GLYATL3
Glycine N-acyltransferase-like protein 3
Also known as: bA28H17.2, C6orf140, GLYL3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q5SZD4
- Gene
- GLYATL3
- Ensembl
- ENSG00000203972
- Chromosome
- 6
- Canonical length
- 288 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted intracellular proteins
OverviewNCBI Gene
Predicted to enable glycine N-acyltransferase activity. Predicted to be involved in lipid metabolic process. Predicted to be located in mitochondrion. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
288 residues, UniProt reviewed canonical sequence.
>Q5SZD4|GLYATL3
1 MLVLNCSTKL LILEKMLKSC FPESLKVYGA VMNINRGNPF QKEVVLDSWP DFKAVITRRQ
61 REAETDNLDH YTNAYAVFYK DVRAYRQLLE ECDVFNWDQV FQIQGLQSEL YDVSKAVANS
121 KQLNIKLTSF KAVHFSPVSS LPDTSFLKGP SPRLTYLSVA NADLLNRTWS RGGNEQCLRY
181 IANLISCFPS VCVRDEKGNP VSWSITDQFA TMCHGYTLPE HRRKGYSRLV ALTLARKLQS
241 RGFPSQGNVL DDNTASISLL KSLHAEFLPC RFHRLILTPA TFSGLPHLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GLYATL3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 1.1 nTPM
Expression across tissuesHPA
Tissue
- liver: 1.1 nTPM
- rectum: 0.4 nTPM
- colon: 0.2 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
Single-cell type
- neuroendocrine cells: 10 nCPM
- pancreatic acinar cells: 4.8 nCPM
- endometrial luminal cells: 3.5 nCPM
- endometrial ciliated cells: 3 nCPM
- endometrial glandular cells: 1.8 nCPM
- thymocytes: 1.7 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.4
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.74
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GLYATL3 as an antibody target. Whether an autoantibody or antibody against GLYATL3 could matter depends on whether native GLYATL3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GLYATL3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label GLYATL3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...